(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 1. The HIF1 pathway in normoxia (A) and hypoxia (B). (A) HIF1
hydroxylation and degradation in the presence of oxygen involves: (1) the independent oxidation-reduction reactions of ascorbate (Asc) and iron (Fe); (2) and (3) prolyl hydroxlyase 2 (PHD2) binding to Fe, 2-oxoglutarate (2OG), and O2; (4) PHD2 hydroxylation of HIF1
; (5) unbound hydroxylated HIF1
moving in the cell cytoplasm; (6) the von Hippel Lindau (VHL)-Elongin B (EB)-Elongin C (EC) complex ubiquitylating HIF1
; and (7) HIF1
degradation. A change in shading of HIF1
indicates addition of a hydroxyl group. (B) In hypoxia, HIF1
enters the nucleus, where hydroxylation, but no degradation occurs. (1) and (2) PHD2 binding to Fe, 2OG and Asc, but not O2. (3) The protein inhibitor of growth 4 (ING4) binding to PHD2 may regulate HIF1
transcriptional activity and (4) block HIF1
-HIF1ß binding. When HIF1
-HIF1ß binding occurs, the HIF1 dimer can transcriptionally activate genes at the hypoxia response element (HRE) site.